Grant: Master's Award: Canada Graduate Scholarships
University of Toronto
$17,500.00
Investigating the Role of Proteolytic Cleavage in the Differential Regulation of Hypoxia-Inducible Factor a Paralogs
FY 2022-23
Summary
Oxygen is essential for cellular survival, enabling energy production to power diverse cellular processes. When oxygen levels decrease—known as hypoxia—cells adapt in order to maintain energy supplies and survive. A key protein in this adaptive process is known as hypoxia-inducible factor (HIF). HIF? protein levels rise in hypoxia, allowing it to interact with its partner HIF? and activate genes to initiate the hypoxic response.
HIF1? and HIF2? are the two best-studied forms of HIF?. While similar, they can activate different genes and are regulated differently in low oxygen conditions. Some potential mechanisms behind the different regulation patterns of HIF-1? and HIF-2? have been investigated. However, our group has identified for the first time that HIF1?, but not HIF2?, is cleaved by an enzyme that breaks proteins into smaller pieces—also known as a protease. We are interested in investigating if HIF1? protease cleavage contributes to the different HIF? regulation patterns seen in hypoxia.
This work aims to identify the exact protease responsible for HIF-1? cleavage in vitro. We also intend to determine if this cleavage occurs within cells. By doing so, we will be able to understand HIF? activity and regulation better. This work also has broader applications to health as many conditions and diseases are associated with low oxygen levels. Notably, HIF1? and HIF2? have been associated with cancer development and are attractive drug targets. Specifically targeting a single form of HIF?, however, is difficult. Our work could help highlight ways to specifically target one form of HIF? or the other. This could improve the specificity and efficiency of HIF? targeted cancer therapy.
Department
Program
Master's Award: Canada Graduate Scholarships
Recipient
Location
Ontario, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database
As published
Id
486347
Name
HUBERT MIA
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Investigating the Role of Proteolytic Cleavage in the Differential Regulation of Hypoxia-Inducible Factor a Paralogs
Programtype2
Studentship Programs
Orgnameinp2
University of Toronto
Cihramount2
$17,500
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Cancer; Cathepsin; Cell Signalling; Cysteine Protease; Hypoxia; Molecular Biology; Protein Regulation
Abstract
Oxygen is essential for cellular survival, enabling energy production to power diverse cellular processes. When oxygen levels decrease—known as hypoxia—cells adapt in order to maintain energy supplies and survive. A key protein in this adaptive process is known as hypoxia-inducible factor (HIF). HIF? protein levels rise in hypoxia, allowing it to interact with its partner HIF? and activate genes to initiate the hypoxic response.
HIF1? and HIF2? are the two best-studied forms of HIF?. While similar, they can activate different genes and are regulated differently in low oxygen conditions. Some potential mechanisms behind the different regulation patterns of HIF-1? and HIF-2? have been investigated. However, our group has identified for the first time that HIF1?, but not HIF2?, is cleaved by an enzyme that breaks proteins into smaller pieces—also known as a protease. We are interested in investigating if HIF1? protease cleavage contributes to the different HIF? regulation patterns seen in hypoxia.
This work aims to identify the exact protease responsible for HIF-1? cleavage in vitro. We also intend to determine if this cleavage occurs within cells. By doing so, we will be able to understand HIF? activity and regulation better. This work also has broader applications to health as many conditions and diseases are associated with low oxygen levels. Notably, HIF1? and HIF2? have been associated with cancer development and are attractive drug targets. Specifically targeting a single form of HIF?, however, is difficult. Our work could help highlight ways to specifically target one form of HIF? or the other. This could improve the specificity and efficiency of HIF? targeted cancer therapy.
Competitiondate
202212
Approvedterm2
1 yr 0 mth
Pinamesdelim
HUBERT, MIA
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $17,500~ $0~